New Slow-Release pill for muscle disease tested in healthy volunteers
NCT ID NCT07154095
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new sustained-release (long-acting) version of pyridostigmine, a drug used for myasthenia gravis (a muscle weakness disease). Forty healthy Chinese adults took both the new long-acting tablet and the standard immediate-release tablet at different times to compare how the drug moves through the body and to check for side effects. The goal is to see if the new version can provide steady drug levels with fewer daily doses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pyridostigmine
What this could lead to
If successful, this sustained-release tablet could allow people with myasthenia gravis to take medication less often while maintaining stable drug levels.
What could go wrong
This is an early-phase study in healthy volunteers, not patients. The new tablet may not work better or could cause unexpected side effects when tested in people with the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Second University Hospital
Chengdu, China